4:36 PM
 | 
Jul 05, 2013
 |  BC Extra  |  Company News

G-BA opts not to assess three older drugs

Germany's Federal Joint Committee (G-BA) said it will not conduct benefit assessments for three drugs launched before drug pricing law AMNOG took effect which it had previously said it would assess. G-BA noted that data exclusivity for the drugs -- osteoporosis drugs...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >